Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists…
26 employees brightmindsbio.com
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
News 2026-05-27
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
News release - English.pdf
Results 2026-05-19
Interim MD&A - English.pdf
Results 2026-05-19
Interim financial statements/report – English.pdf
Ownership 2026-04-30
Vasilkevich, Alex sold +$303k
Insider trading – 2026-04-30
1 insider · −$303k net
News 2026-02-19
Other.pdf
News 2026-02-19
Other.pdf
Results 2026-02-12 Financials
Interim financial statements/report – English.pdf
Results 2026-02-12 Financials
Interim MD&A - English.pdf
Transactions 2026-01-09 Financing
Bright Minds Biosciences Inc. Announces Positive Topline Results from Phase 2 BREAKTHROUGH Clinical Trial of BMB-101 and Completes US$175 Million Public Offering
Material change report - English.pdf
Transactions 2026-01-09 Financing
BRIGHT MINDS BIOSCIENCES ANNOUNCES CLOSING OF US$175 MILLION PUBLIC OFFERING
News release - English.pdf
Transactions 2026-01-09
Other material contracts - English.pdf
News 2026-01-09
Offering material - English.pdf
Transactions 2026-01-08 Financing
BRIGHT MINDS BIOSCIENCES ANNOUNCES PRICING OF UPSIZED US$175 MILLION PUBLIC OFFERING OF COMMON STOCK
News release - English.pdf
Transactions 2026-01-06 Financing
BRIGHT MINDS BIOSCIENCES ANNOUNCES LAUNCH OF US$100 MILLION PUBLIC OFFERING
News release - English.pdf
Results 2026-01-06
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)
News release - English.pdf
Results 2026-01-06
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
News release - English.pdf
Results 2025-12-24 Financials
Annual information form - English.pdf
Results 2025-12-24 Financials
Annual MD&A - English.pdf
Results 2025-12-24 Financials
Audited annual financial statements – English.pdf
News 2025-11-07
News release - English.pdf
News 2025-11-07
News release - English.pdf
News 2025-09-05
News release - English.pdf
Transactions 2025-09-03
Other material contracts - English.pdf
News 2025-09-03
Offering material - English.pdf
Results 2025-08-14 Financials
Interim MD&A - English.pdf
Results 2025-08-14 Financials
Interim financial statements/report – English.pdf
Ownership 2025-04-06
Pedersen, Jan Torleif sold +$121k
Insider trading – 2025-04-06
1 insider · −$121k net
Ownership 2025-03-06
Bottler, Nils sold +$181k
Insider trading – 2025-03-06
1 insider · −$181k net
Ownership 2024-12-10
Pedersen, Jan Torleif sold +$1.4M
Insider trading – 2024-12-10
1 insider · −$1.4M net
Ownership 2024-11-13
Bottler, Nils sold +$653k
Insider trading – 2024-11-13
1 insider · −$653k net
Ownership 2024-11-11
Cheung, Ryan sold +$399k
Insider trading – 2024-11-11
1 insider · −$399k net
Ownership 2024-11-08
2 insiders · +$3.8M net
Insider trading – 2024-11-08
2 insiders · +$3.8M net
Ownership 2024-11-07
Fryzuk, Jeremy bought +$100k
Insider trading – 2024-11-07
1 insider · +$100k net
Ownership 2024-11-05
2 insiders · +$3.3M net
Insider trading – 2024-11-05
2 insiders · +$3.3M net
Ownership 2024-11-01
2 insiders · +$4.7M net
Insider trading – 2024-11-01
2 insiders · +$4.7M net
Ownership 2024-10-23
Fryzuk, Jeremy sold +$97k
Insider trading – 2024-10-23
1 insider · −$97k net